AI Terminal
Spexis AG
Legal Proceedings Report • Dec 5, 2023
957_rns_2023-12-05_1e7527e2-045b-4ed3-be10-f528b2c94e31.html
Legal Proceedings Report
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 5 December 2023 07:15
Spexis is Granted Debt-Restructuring Moratorium
Spexis AG / Key word(s): Miscellaneous
05-Dec-2023 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
**Ad hoc announcement pursuant to Art. 53 LR
**
Spexis is Granted Debt-Restructuring Moratorium
Allschwil, Switzerland, December 5, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has been formally granted moratorium status ( Nachlassstundung ) by the Western District Court of the Canton Basel-Landschaft. This announcement follows the Company’s announcement of November 29 th indicating that a formal request for such status had been submitted.
The plan submitted to the court included a cost reduction, a restructuring of the debt with major secured and unsecured creditors (such as SPRIM Global Investments), a continuation of the COPILOT trial in case additional financing can be obtained and a sale of other assets. All of these initiatives are being implemented by Spexis.
The Company will issue further milestone announcements as parts of its moratorium plan are achieved.
About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com .
For further information please contact:
| For Investors: Stephen Jasper Managing Director Gilmartin Group [email protected] For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 [email protected] |
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of Inside Information
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | [email protected] |
| Internet: | www.spexisbio.com |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1789023 |
| End of Announcement | EQS News Service |